rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600R-mutant melanoma accounts for a significant number of cases even in single-institution practices.
|
31305324 |
2020 |
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
By using genetic material collected noninvasively and to further validate the PLA, somatic hotspot mutations in genes known to be drivers of early melanoma development (BRAF other than V600E, NRAS, and the TERT promoter) can also be identified.
|
30500343 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The most prevalent BRAF mutation, V600E, occurs frequently in melanoma and other cancers.
|
31152574 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We established vemurafenib-resistant (VR) cells from three BRAF (V600E)-mutated melanoma lines (C32, HMY-1, and SK-MEL-28) and evaluated the mechanism of acquired resistance of VR cells by water-soluble tetrazolium salts assay, western blot, real-time quantitative PCR, and immunofluorescent microscopy.
|
30920401 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we present a case of pulmonary melanocytic nevus, involving a BRAF gene mutation (V600E), and we discuss the potential significance of this condition as a precursor to pulmonary malignant melanoma.
|
31556191 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study reviews the management of BRAF-V600E mutant melanoma with ependymal involvement.
|
30972290 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The data reveal a very close link between the two methods, supporting the use of the V600E as a primary screen for BRAF mutations in malignant melanoma.
|
30870099 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Chronic sun-damaged (CSD) melanoma represents 10%-20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load.
|
31811783 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we discuss the role of ERK signaling in cell fate, in driving melanoma, and in resistance mechanisms to current BRAF-V600E melanoma treatments.
|
31190430 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Accordingly, we evaluated the phenotypical and molecular changes of isogeneic human V600E BRAF-mutant melanoma cell line pairs pre- and post-treatment with vemurafenib.
|
31514305 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Our data suggest indoor tanning may promote melanomas that arise in skin with low-chronic sun-induced damage through BRAF V600E-mediated melanomagenesis.
|
30923800 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
|
31223037 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Of these inhibitors, encorafenib and binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E/K-mutated melanoma in June 2018.
|
31050693 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein.
|
31401373 |
2019 |